This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n12http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00082/identifier/drugbank/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/mesh/concept/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00082/identifier/national-drug-code-directory/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n19http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00082/identifier/genbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00082/identifier/uniprotkb/
n5http://linked.opendata.cz/resource/drugbank/patent/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/medicinal-product/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00082/identifier/pharmgkb/
n8http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00082
rdf:type
n3:Drug
n3:description
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
n3:dosage
n4:271B43BB-363D-11E5-9242-09173F13E4C5 n4:271B43BC-363D-11E5-9242-09173F13E4C5 n4:271B43BD-363D-11E5-9242-09173F13E4C5 n4:271B43BA-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
~6 days
n3:indication
Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
n3:manufacturer
n10:271B43B6-363D-11E5-9242-09173F13E4C5
owl:sameAs
n16:DB00082 n19:DB00082
dcterms:title
Pegvisomant
adms:identifier
n21:PA164749630 n23:P58756 n24:AF374232 n25:0009-5176-01 n26:DB00082
n3:mechanismOfAction
Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.
n3:packager
n10:271B43B3-363D-11E5-9242-09173F13E4C5 n10:271B43B4-363D-11E5-9242-09173F13E4C5 n10:271B43B5-363D-11E5-9242-09173F13E4C5
n3:patent
n5:2102129 n5:2230492 n5:5849535 n5:5350836
n3:synonym
Growth hormone Pituitary growth hormone GH Growth hormone 1 GH-N Somatotropin precursor
n3:volumeOfDistribution
* 7 L
n6:hasAHFSCode
n7:68-30-08
n3:synthesisReference
Mandayam J. Narasimhan, John A. Anderson, "Process for the large scale production of human growth hormone by serial secondary suspension culture." U.S. Patent US4124448, issued January, 1963.
n8:hasConcept
n9:M0360672
foaf:page
n12:somavert.htm n17:pegvisomant.html
n3:Molecular-Formula
n13:271B43C2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n13:271B43C1-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n14:H01AX01
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
218620-50-9
n3:category
n3:clearance
* 36 - 28 mL/h [SC doses ranging from 10 to 20 mg/day]
n3:containedIn
n22:271B43B9-363D-11E5-9242-09173F13E4C5 n22:271B43B7-363D-11E5-9242-09173F13E4C5 n22:271B43B8-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n13:271B43BF-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n13:271B43C0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n13:271B43BE-363D-11E5-9242-09173F13E4C5